BMS and Cellares Enter $380m CAR T Cell Therapy Capacity & Supply Deal
Bristol Myers Squibb (BMS) announced on Monday it has entered a worldwide capacity reservation and supply agreement with the California-headquartered Integrated
Read moreBristol Myers Squibb (BMS) announced on Monday it has entered a worldwide capacity reservation and supply agreement with the California-headquartered Integrated
Read moreVentus Therapeutics, a US-based clinical-stage biopharmaceutical company leveraging its exclusive structural biology and computational chemistry platform, ReSOLVE™, has disclosed promising
Read morePreclinical data shows that Nutcracker’s mRNA drug candidate NTX-470 effectively targets CD3 T cells, demonstrating selective engagement with minimal unintended
Read moreVertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology firm dedicated to pioneering protein-based immunotherapies, jointly announced the signing
Read morePfizer has announced encouraging findings from its ongoing pivotal Phase 3 clinical trial, known as MONeT (RSV IMmunizatiON Study for
Read moreThe U.S. Food and Drug Administration has approved the use of cell therapies developed by Johnson & Johnson (JNJ.N) and Bristol Myers Squibb (BMY.N) for treating
Read moreThe US FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as the first tumor-agnostic HER2-directed therapy for the
Read moreAstraZeneca has announced it is set to acquire Amolyt Pharma, a French clinical-stage biotechnology company focused on developing novel treatments
Read moreAmerican clinical-stage biotechnology company Vaxart, Inc. has announced that the United States Biomedical Advanced Research and Development Authority (BARDA) granted
Read moreLutathera®, developed by Swiss drugmaker Novartis has demonstrated a substantial 72% reduction in the risk of disease progression or death
Read more